- Products & Solutions
- FDA IVD
- About Us
- News & Events
- Contact
- Additional Sites
BUHLMANN News
Visit BUHLMANN at DDW 2022
Assays Offerings Assays Offerings: We offer the broadest fecal calprotectin (fCAL) product range in the industry, available in the United ...
Buhlmann – Next Generation Food Allergy Drug Development Summit
Next Generation Food Allergy Drug Development Summit, July 20-22, 2021: BUHLMANN is proud to partner with this event, specifically focused ...
Digestive Disease Week 2021
Assays Offerings We offer the broadest fecal calprotectin (fCAL) product range in the industry, available in the United States, including ...
Visit BUHLMANN at AACC 2021 (LIVE)
Assays Offerings Assays Offerings: BUHLMANN Diagnostic Corp (BDC), offers the broadest fecal calprotectin (fCAL) product range in the industry, available ...
BUHLMANN Diagnostic Corp – New Partner Channel Agreement with Roche Diagnostics
Announcement BUHLMANN Diagnostic Corp is pleased to announce a new partner channel agreement with Roche Diagnostics for the launch and ...
Educational Webinar recording from AMLI presentation by Dr Arne Roseth
BÜHLMANN fCAL® ELISA is FDA 510(k) cleared. For in vitro Diagnostic Use. Health Canada License: 80726 Abstract Inflammatory Bowel Disease (IBD) is a ...
Use of basophil activation in oral immunotherapy
New JACI paper from Patil et al: Food allergy is a growing public health burden in children and adults all ...
CALEX Cap Promotion
BÜHLMANN fCAL® turbo + CALEX® Cap (K191718): FDA 510(k) cleared. For in vitro Diagnostic Use. Health Canada License: 98839 CALEX® Cap CALEX® Cap is an ...
